GL · Q4 2025 Earnings

Q: Asked about elevated first-year lapses in direct-to-consumer and Liberty National channels, and clarification on MedSupp vs. MedAdvantage market dynamics given recent claims trends.

Management attributed higher DTC lapses to Internet channel mix (which naturally has higher lapses) but noted it was still higher than anticipated. On MedSupp, management confirmed claims trends stabilized in Q3-Q4 2025 (unlike elevated trends in 2024) and stated approved rate increases are adequate to restore 10-12% normal margins in 2026-2027. Management highlighted favorable Medicare Advantage market dynamics benefiting MedSupp demand.

Q: Questioned whether American Income agent productivity gains in Q4 (2% agent count drop with 10% sales growth) reflect unsustainable trends, and whether new retention initiatives mean prior incentives were inadequate.

Management explained Q4 agent count declines are seasonal and not uncommon (occurred in 3 of last 4 years). Productivity gains driven by: agent count growth as leading indicator (Q4 2024 was 7%, carried forward), premium per sale increases, and quality lead conversion from DTC to American Income. Management clarified that new manager incentive tweaks focus on balancing sales growth with retention, but prior incentives existed—the 2026 changes are refinements based on experience.

Q: Asked whether technology-driven sales and efficiency tailwinds (from branding, lead-sharing, sourcing) are largely exhausted or if more upside remains.

Management stated significant tailwinds remain unlocked. On agency side, new technology options coming online in 2026-2027 expected to drive agent productivity gains faster than agent count growth. On DTC, continued investment in marketing targeting and customer experience conversion will drive further efficiency gains. Management characterized prior work as foundational but not complete.

Q: Asked about portfolio exposure to software and AI disruption risk, and any de-risking activities undertaken.

Management provided detailed exposure assessment: less than $15 million in software companies within alternative portfolio; private credit ~1% of invested assets (unchanged); less than 2% of fixed maturity portfolio in tech sector. Primary tech exposure in hardware/data service providers with ~$50 million in names susceptible to AI displacement, but with protective moats. AI disruption considered as ongoing risk factor in investment matrix.

Q: Asked for details on initial Bermuda reinsurance transaction, timeline for reciprocal jurisdiction approval, and expected lift to excess cash flows in 2026-2027.

Management disclosed initial transaction involved $1.2 billion of statutory reserves transferred in 2025. Confirmed plan to reinsure new business and incremental in-force business in 2026. Reciprocal jurisdiction possible but subject to regulatory approval, likely mid-year discussion. No benefit built into 2026 plan; any distributions toward year-end if approved. Potential $200 million annual distributions anticipated starting 2027 if reciprocal status achieved.

Bullish

Globe Life

Reported February 4, 2026

30-second summary

Globe Life closed FY2025 at $14.52 non-GAAP EPS — squarely inside the prior $14.40–$14.60 guide — and raised the FY2026 EPS range by $0.35 at the midpoint to $14.95–$15.65, layering in segment-level premium, margin, and capital-return targets that were not previously disclosed. Q4 revenue was $1.52B (+5% YoY), normalized earnings growth ex-assumption updates is ~10%, and the Bermuda captive executed an initial $1.2B statutory reserve transfer in 2025 — but the $200M annual parent cash-flow uplift is now explicitly a 2027+ event, with zero benefit baked into the 2026 plan. The bull-case mortality tailwind held, DTC life net sales kept turning, and management is now willing to anchor multi-year guidance to a normalized run-rate.

Headline numbers

EPS

Q4 FY2025

$3.39

Revenue

Q4 FY2025

$1.52B

+5.0% YoY

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$1.52B	+5.0%	$1.51B	+0.5%
EPS	$3.39	—	$4.81	-29.5%

Guidance

Globe Life raised FY2026 EPS guidance by $0.35 at midpoint to $14.95–$15.65 and introduced comprehensive forward guidance across premium growth, underwriting margins, and capital allocation metrics, reflecting operational momentum and confidence in favorable trends through 2026.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Net Operating Income Per Share	FY2025	$14.40 to $14.60	$14.52	in-line	Beat

New guidance

Metric	Period	Guide	YoY
Total Premium Revenue Growth	FY2026	7% to 8%	—
Life Premium Revenue Growth	FY2026	4% to 4.5%	—
Health Premium Revenue Growth	FY2026	14% to 16%	—
Life Underwriting Margin as % of Premium	FY2026	41.5% to 44.5%	—
Health Underwriting Margin as % of Premium	FY2026	23% to 27%	—
Net Investment Income Growth	FY2026	3% to 4%	—
Parent Excess Cash Flow	FY2026	$625 million to $675 million	—
Share Repurchases	FY2026	$535 million to $585 million	—
Dividend Payments	FY2026	$85 million to $90 million	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Net Operating Income Per Share	FY2026	$14.60 to $15.30	$14.95 to $15.65	+$0.35–0.35 midpoint increase	Raised

Segment performance

Q4 FY2025

Segment	Q4 FY2025	YoY
Life Insurance - American Income	$0.46B	+6.0%
Life Insurance - Liberty National	$0.1B	+4.0%
Life Insurance - Direct to Consumer	$0.24B	—
Health Insurance - United American	$0.17B	+14.0%
Health Insurance - Family Heritage	$0.12B	+10.0%
Life Insurance Premium	$0.85B	+3.0%
Health Insurance Premium	$0.39B	+9.0%

Capital & returns

Q4 FY2025

Segment	Q4 FY2025
Return on Equity (ROE) - Net Income	20.9%
Return on Equity (ROE) excluding AOCI - NOI	16.0%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Net Operating Income (NOI) per Share - Q4	$3.39
Net Operating Income (NOI) per Share - FY2025	$14.52
Life Net Sales Growth - Q4	+11%
Health Net Sales Growth - Q4	+71%
Administrative Expense Ratio	7.4% of premium
Producing Agent Count Growth - American Income	-2% YoY

Management tone

Q1 capital-flexibility narrative → Q2 mortality tailwind reaffirmation → Q3 multi-year confidence signal → Q4 segment-level disclosure escalation.

Disclosure granularity stepped up another notch. Q2 introduced FY guidance refresh; Q3 initiated FY2026 EPS one year early; Q4 layered in segment-by-segment premium growth (life 4–4.5%, health 14–16%), separate life and health margin bands, net investment income growth (3–4%), and an itemized capital-return stack (excess cash flow, buybacks, dividends). The anchor quote: "Normalized earnings per share growth, which removes the impact of assumption updates in both 2025 and the midpoint of 2026, is approximately 10%." Management is now willing to publish the normalization math itself — a level of transparency that didn't exist at the start of 2025 and that pre-empts the analyst skepticism that flared post-Fuzzy Panda 2024.

DTC narrative completed the arc from drag → turnaround → operating model. Q2 called the channel a "turnaround" after 16 quarters of declines; Q3 saw -0.6% premium with +13% net sales; Q4 prints flat premium with net sales +24%. Management said on the call: "We are excited to see this continued sales turnaround from the declining trend of recent years." Two quarters of consecutive net-sales acceleration and a now-zero premium drag validates the lead-conversion technology spend and supports the FY2026 4–4.5% life premium guide.

Bermuda moved from binary catalyst to staged process with explicit gating. Q2 was concept; Q3 was execution-by-year-end; Q4 confirms the first $1.2B statutory reserve transfer happened in 2025 — and then explicitly removes any 2026 EPS or cash-flow benefit. The new framing: reciprocal jurisdiction approval likely mid-2026, distributions (if any) toward year-end 2026, full ~$200M annual uplift starting 2027. "We anticipate parents' annual excess cash flow will increase over time toward $200 million as earnings emerge from reinsurance additional, in-force, and new business." Management is choosing to under-promise rather than tee up a 2026 disappointment.

Agent retention shifted from generic business dynamic to named initiative. Q3 emphasized recruiting (AIL hires +17%); Q4 acknowledges AIL agent turnover "exceeded expectations" and announces a new manager-incentive structure to balance recruiting with retention. Management was explicit that prior incentives existed and the 2026 changes are refinements, not corrections — but the framing change matters. American Income's 2026 sales growth is now guided slower than 2025 specifically because management wants agent-count growth to come in slightly under sales growth via productivity, not headcount adds.

Investment portfolio commentary turned defensive on credit quality. New this quarter: BBB allocation is declining because narrower spreads make higher-rated bonds the better risk-adjusted choice. Combined with the AI-disruption portfolio review (less than $15M in alternative-portfolio software, <2% of fixed maturities in tech), management is positioning the portfolio for an environment where credit spreads stay tight and tail risks bite harder.

Recurring themes management leaned on this quarter:

Favorable mortality trends sustaining underwriting margin expansionHealth premium growth acceleration driven by Medicare supplement rate increases and beneficiary migrationDirect-to-consumer technology-enabled sales recovery and channel lead optimizationAgent count growth stabilizing across exclusive agencies with selective retention focusInvestment yield stability through commercial mortgage and partnership allocation amid compressed credit spreadsBermuda reinsurance structure anticipated to unlock $200M excess cash flow over time

Risks management surfaced:

Medicare marketplace dynamics remain uncertain and could require estimate refinementsSeasonally high claims in Q1 at United American will temporarily depress health margin percentagesLower average earned yield on short-term direct commercial mortgage loans and limited partnership investmentsAgent turnover at American Income exceeded expectations in Q4Net unrealized loss position of $1.2 billion on fixed maturity portfolio due to higher market rates

Q&A highlights

Jimmy Buller · J.P. Morgan

Asked about elevated first-year lapses in direct-to-consumer and Liberty National channels, and clarification on MedSupp vs. MedAdvantage market dynamics given recent claims trends.

Management attributed higher DTC lapses to Internet channel mix (which naturally has higher lapses) but noted it was still higher than anticipated. On MedSupp, management confirmed claims trends stabilized in Q3-Q4 2025 (unlike elevated trends in 2024) and stated approved rate increases are adequate to restore 10-12% normal margins in 2026-2027. Management highlighted favorable Medicare Advantage market dynamics benefiting MedSupp demand.

Q1 DTC and Liberty National lapses were higher than expectedMedSupp margins expected to reach 10-11% in Q2-Q4 2026Claim trends stabilized in Q3-Q4 2025, less than anticipated in rate increasesQ4 slightly below the 10-11% range due to seasonality

Andrew Klagerman · TD Cowan

Questioned whether American Income agent productivity gains in Q4 (2% agent count drop with 10% sales growth) reflect unsustainable trends, and whether new retention initiatives mean prior incentives were inadequate.

Management explained Q4 agent count declines are seasonal and not uncommon (occurred in 3 of last 4 years). Productivity gains driven by: agent count growth as leading indicator (Q4 2024 was 7%, carried forward), premium per sale increases, and quality lead conversion from DTC to American Income. Management clarified that new manager incentive tweaks focus on balancing sales growth with retention, but prior incentives existed—the 2026 changes are refinements based on experience.

Q4 2024 agent count growth was 7%, which carried forward into Q4 2025 salesQ1-Q3 2025 agent count growth was low single-digitPremium per sale is up vs. prior year Q4American Income sales grew high single-digit in 2025

Wilma Burtis · Raymond James

Asked whether technology-driven sales and efficiency tailwinds (from branding, lead-sharing, sourcing) are largely exhausted or if more upside remains.

Management stated significant tailwinds remain unlocked. On agency side, new technology options coming online in 2026-2027 expected to drive agent productivity gains faster than agent count growth. On DTC, continued investment in marketing targeting and customer experience conversion will drive further efficiency gains. Management characterized prior work as foundational but not complete.

Technology enhancements coming online in 2026-2027Goal is to grow sales faster than agent count through productivityDTC online channel is primary sales growth driverFocus on converting leads/inquiries into sales and retention through customer experience

John Barnage · Piper Sandler

Asked about portfolio exposure to software and AI disruption risk, and any de-risking activities undertaken.

Management provided detailed exposure assessment: less than $15 million in software companies within alternative portfolio; private credit ~1% of invested assets (unchanged); less than 2% of fixed maturity portfolio in tech sector. Primary tech exposure in hardware/data service providers with ~$50 million in names susceptible to AI displacement, but with protective moats. AI disruption considered as ongoing risk factor in investment matrix.

Less than $15 million software exposure in alternative portfolioPrivate credit 1% of total invested assetsLess than 2% of fixed maturity portfolio in technology sectorApproximately $50 million in tech-related hardware/data service exposure

Wes Carmichael · Wells Fargo

Asked for details on initial Bermuda reinsurance transaction, timeline for reciprocal jurisdiction approval, and expected lift to excess cash flows in 2026-2027.

Management disclosed initial transaction involved $1.2 billion of statutory reserves transferred in 2025. Confirmed plan to reinsure new business and incremental in-force business in 2026. Reciprocal jurisdiction possible but subject to regulatory approval, likely mid-year discussion. No benefit built into 2026 plan; any distributions toward year-end if approved. Potential $200 million annual distributions anticipated starting 2027 if reciprocal status achieved.

Initial Bermuda transaction: $1.2 billion statutory reserves transferredPlan to reinsure additional new and in-force business in 2026Reciprocal jurisdiction approval discussions expected mid-2026Any 2026 distributions would be toward year-end if approved

Answers to last quarter's watch list

Bermuda captive execution by year-end. Resolved on execution: the initial transaction transferred $1.2B of statutory reserves in 2025. But the cash-flow benefit is now explicitly gated — no 2026 P&L or excess cash flow uplift, with $200M annual run-rate not arriving until 2027 at earliest, and only if reciprocal-jurisdiction status is granted mid-2026. Status: Resolved positively on execution; the structural capital-return uplift is now firmly a 2027 story.

DTC life premium turns positive YoY. DTC life premium was flat (0%) in Q4 versus -0.6% in Q3 and -1% in Q2. Net life sales were +24% YoY and management explicitly called it a "continued sales turnaround." Premium has now crossed from negative to zero; a positive print in Q1 2026 is the next milestone. Status: Continue monitoring (resolved to flat; positive print still pending).

Normalized life UW margin trajectory. Management did not isolate a normalized Q4 life UW margin figure in the disclosed materials, but anchored FY2026 life UW margin guide at 41.5–44.5% — a band that brackets the Q3 normalized 41.5% and acknowledges 2025's assumption-update gain doesn't recur. Normalized 10% EPS growth supports the upper half of the FY2026 range. Status: Continue monitoring.

Health underwriting margin holds in the 25–27% guide band. FY2026 health UW margin guide stepped down to 23–27% (vs. FY2025 raised band of 25–27%), with management explicitly flagging Q1 2026 will run below the range on United American seasonality before recovering 10–11% margins in Q2–Q4. Sustained outperformance from FY2025 did not translate into a band raise. Status: Resolved negatively (band widened lower, not raised).

Worksite platform and recruiting CRM rollout progress at Liberty National. Liberty National Q4 premium growth of +4% is consistent with prior quarters; management did not provide specific worksite-platform conversion metrics on this print. The qualitative framing of "technology options coming online in 2026–2027" suggests the rollout is on track but management isn't yet ready to quantify productivity gains. Status: Continue monitoring.

What to watch into next quarter

DTC life premium prints positive YoY in Q1 2026. Premium has gone -1% → -0.6% → 0% over three quarters with net sales accelerating to +24%. A negative print would suggest the inflection is stalling; +1% or better validates reinstating marketing spend.

Q1 2026 health UW margin trough depth. Management telegraphed Q1 will run below the 10–11% normalized MedSupp margin band on United American seasonality. A print materially below 10% — particularly if accompanied by softer commentary on rate adequacy — would call into question whether the FY2026 23–27% band is sustainable.

American Income producing agent count trajectory. Q4 was -2% YoY; management says 2026 agent count growth will run "slightly slower than sales growth" by design. Watch whether the trough is Q4 2025 or whether the negative print persists into Q1 2026 — sustained declines would put pressure on the FY2026 4–4.5% life premium guide.

Bermuda reciprocal-jurisdiction approval cadence. Management targets a mid-2026 regulatory discussion. Any signal in Q1 or Q2 that the approval is on track for 2026 (vs. slipping to 2027) materially affects the 2027 cash-flow uplift timing.

FY2026 EPS guide trajectory. The $0.35 midpoint raise this quarter is the early read on management's confidence. Watch whether Q1 brings another raise (validating durability) or a hold (signaling 2025-style mortality tailwinds are now fully priced into the guide).

United American 2026 sales trajectory vs. flat guide. Management is projecting flat sales after doubling in 2025. A positive surprise would extend the health-segment growth story; a sharper-than-flat decline would suggest the 2025 doubling pulled forward 2026 demand from Medicare Advantage disruption.

Sources

Globe Life Q4 FY2025 earnings release — https://www.sec.gov/Archives/edgar/data/320335/000032033526000029/q4fy2025earningsrelease.htm
Globe Life Q4 FY2025 earnings call commentary (J.P. Morgan, TD Cowen, Piper Sandler, Wells Fargo, Raymond James exchanges)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.